KCM
KZR

Kennedy Capital Management’s Kezar Life Sciences KZR Stock Holding History

Kennedy Capital Management’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-8,033
Closed -$251K – 682
2023
Q1 		$251K Buy
8,033
+199
+3% +$11.5K 0.01% 593
2022
Q4 		$551K Sell
7,834
-9
-0.1% -$667 0.02% 549
2022
Q3 		$675K Buy
7,843
+1
+0% +$97 0.02% 526
2022
Q2 		$649K Sell
7,842
-29,092
-79% -$2.57M 0.02% 521
2022
Q1 		$6.14M Sell
36,934
-7,122
-16% -$1.02M 0.15% 260
2021
Q4 		$7.37M Sell
44,056
-1,059
-2% -$120K 0.16% 245
2021
Q3 		$3.9M Sell
45,115
-774
-2% -$51.2K 0.09% 387
2021
Q2 		$2.49M Sell
45,889
-5,066
-10% -$288K 0.05% 469
2021
Q1 		$3.04M Sell
50,955
-1,902
-4% -$111K 0.06% 466
2020
Q4 		$2.76M Sell
52,857
-244
-0.5% -$13.6K 0.06% 463
2020
Q3 		$2.57M Buy
53,101
+29,069
+121% +$1.39M 0.07% 448
2020
Q2 		$1.25M Buy
+24,032
New +$1.21M 0.04% 558

Other funds holding KZR

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Kennedy Capital Management's KZR Position: Q2 2023 in Review

Kennedy Capital Management sold out of Kezar Life Sciences (KZR) in Q2 2023, closing a stake of 8,033 shares — an estimated $251K sold.

Kennedy Capital Management first reported a position in KZR in Q2 2020 and held it in 12 quarters. The position peaked at $7.37M in Q4 2021. 104 funds tracked by Wall St. Rank hold KZR as of Q2 2023.

  • Kennedy Capital Management reported no remaining Kezar Life Sciences position as of Q2 2023 after selling out during the quarter.
  • Kennedy Capital Management sold 8,033 Kezar Life Sciences shares in Q2 2023, an estimated $251K.
  • Kennedy Capital Management first reported a position in Kezar Life Sciences in Q2 2020 and held it in 12 quarters.
  • Kennedy Capital Management's Kezar Life Sciences position peaked at $7.37M in Q4 2021.
  • 104 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q2 2023.

Based on Kennedy Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.